The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Consensus and debate in newly diagnosed multiple myeloma: autoSCT, immunotherapy, & MRD
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, discusses the key points from a roundtable discussion on newly diagnosed multiple myeloma (NDMM), highlighting a consensus on the role of autologous stem cell transplantation (autoSCT) and the potential of immunotherapies. Dr Zamagni notes that while there is agreement on the utility of measurable residual disease (MRD) testing, there is some debate on how to use MRD results to tailor treatment. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.”
Transcript
I think it was quite a consensus, mostly on the fact that autologous stem cell transplantation is still a standard of care for most of us. We were mostly agreeing on this. And that the future is immunotherapy. Immunotherapy since the very beginning, so bispecific or CAR-T integrated with auto-transplant or substituting auto-transplant. So this was quite an agreement. Another agreement was on the MRD use...
I think it was quite a consensus, mostly on the fact that autologous stem cell transplantation is still a standard of care for most of us. We were mostly agreeing on this. And that the future is immunotherapy. Immunotherapy since the very beginning, so bispecific or CAR-T integrated with auto-transplant or substituting auto-transplant. So this was quite an agreement. Another agreement was on the MRD use. For sure newly diagnosed multiple myeloma is the setting where minimal residual disease is mostly useful to tailor treatment. Maybe a field of little disagreement was on how to tailor now on MRD because we do have some data but we do lack some other data so or not all the questions are answered so some of us were more keen to already use MRD to tailor maintenance duration some others were maybe hoping for additional data. So this is still something ongoing. And in the more elderly population, so newly diagnosed non-transplant eligible patients, currently we do have quadruplets and triplets. The integration of immunotherapy is ongoing. For sure the treatment duration is another still open question so on this there are still some controversies because initial data are not fixed duration treatments so it’s work in progress.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
